Loading chat...
MT SB447
Bill
AI Summary
- Prior authorization certifications extended from 3 months to 12 months from the date the health care provider receives approval
- Prior authorization for chronic conditions (lasting 1 year or more) is valid for the duration of the condition, with insurers limited to requesting documentation of the condition's presence no more than once every 12 months
- Prohibits prior authorization for formulary oral or inhaled nonbiologic generic prescription drugs not listed as Medicare Part D specialty tier drugs or controlled substances
- Prohibits prior authorization for prescription drugs treating substance use disorders when prescribed within FDA-labeled dosages
- Requires at least one prior-authorization-exempt prescription drug option for children and one for adults in therapeutic classes including inhaled corticosteroids, short-acting beta-agonists, combination inhalers, and short-acting and long-acting insulins
Legislative Description
Revise laws related to prior authorization
Safety
Last Action
Chapter Number Assigned
5/16/2025
Committee Referrals
Business & Labor3/17/2025
Business, Labor and Economic Affairs2/24/2025
Full Bill Text
No bill text available